Israel is conducting clinical trials of a coronavirus vaccine known as BriLife. According to Xinhua, this vaccine was developed at the Israeli Institute for Biological Research.
It is planned to vaccinate about 80 volunteers in two hospitals in November: half of them will receive the real vaccine, and the rest will receive a placebo.
For three weeks, scientists will monitor whether vaccinated volunteers will develop COVID-19 antibodies. The second phase of testing is scheduled for December.
It will involve 960 volunteers and will include tests for the safety of the vaccine. During the third and final phase - which is planned for the next 6 months - the effectiveness of the vaccine will be tested on a group of up to 30,000 people.